Our lab has shown that MCT1 is predominantly expressed in oligodendrocytes. In neurodegenerative disorders such as ALS, there is a decline in MCT1 expression that exacerbates the disease progression. With that said, my first project aims to identify cell-specific methylation patterns in the MCT1 gene and to also characterize its promoter to further understand MCT1 regulation. To tackle this project I am incorporating a wide range of molecular and genetic techniques and utilizing transgenic mouse models to provide an in vivo system.
Identification and Characterization of Astrocyte subpopulations
This project aims to identify potential subpopulations of astrocytes that may provide different metabolic functions both in normal and disease contexts. In particular, I am utilizing transgenic mouse models that harbor different alterations of the glutamate transporter gene, GLT1.
- Vorobyeva A., Lee R.*, Miller S.*, Kandelwal P., et al. Cyclopamine Modulates Gamma-Secretase Mediated Cleavage of Amyloid Precursor Protein by Altering Subcellular Trafficking, In submission to the Journal of Biological Chemistry.
- Veeraraghavalu K.*, Zhang C.*, Miller S.*, et al. A Role for RXR Agonists in Reducing A-Beta Burden Revisited: No Evidence that Bexarotene Alters A-Beta Levels or Deposition in Vivo. Published in Science, 2013; 349(924):1235505.
- Utreja S., Miller S.J., Saunders A.J. Calcineurin Overexpression Regulates APP Metabolism. Published in the Journal Advances in Alzheimer’s Disease, 2013; 2(3):109-116.
- Chakraborty R.,Vepuri V., Mhatre S., Paddock B., Miller S., et al. Characterization of a Drosophila Alzheimer’s Disease Model: Pharmacological Rescue of Cognitive Defects. Published in PLoS ONE, 2011; 6(6): e20799.